Your CRO partner significantly impacts the success of your MS trial
The development of new medicines targeting multiple sclerosis (MS) can take 10 to 15 years from testing in a laboratory to becoming commercially available. For every 10,000 compounds tested, fewer than one or two become licensed treatments. Many are rejected on the grounds of their safety, quality, and efficacy.1
As a full-service CRO, we have an outstanding track record in starting up and executing MS studies, including beta-interferons, glatiramer acetate monoclonal antibodies, and oral preparations for disease-modifying approaches.